Zoledronic Acid as a Therapeutic Option for Hypercalcemia in Subcutaneous Fat Necrosis: Series of Four Infants
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Subcutaneous fat necrosis (SFN) of the newborn is a self-limiting condition, yet the associated hypercalcemia may result in life-threatening complications. We report a series of four term infants who developed symptomatic hypercalcemia secondary to SFN. Clinical features included firm subcutaneous nodules and elevated serum calcium levels, with suppressed parathyroid hormone (PTH) levels. Management comprises early recognition of SFN-associated hypercalcemia and prompt treatment. We hereby report the use of a single dose of zoledronic acid as an effective therapy for the resolution of hypercalcemia.
Fields of Study & Subjects
Parathyroid Disorders and Treatments
Bone health and treatments
Neonatal skin health care
Publication details
- Journal / source
- Journal of Neonatology
- Publication date
- 26 March 2026
- Language
- EN